US BANCORP \DE\ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$9,845
+959.7%
531
+532.1%
0.00%
Q2 2023$929
-85.7%
84
-82.6%
0.00%
Q1 2023$6,487
-53.7%
483
-51.2%
0.00%
Q3 2022$14,000
+600.0%
989
+678.7%
0.00%
Q1 2022$2,000
+100.0%
127
+126.8%
0.00%
Q4 2021$1,000
-80.0%
56
-71.7%
0.00%
Q1 2021$5,0000.0%198
-7.5%
0.00%
Q4 2020$5,000
+400.0%
214
+872.7%
0.00%
Q3 2020$1,000
-75.0%
22
-75.0%
0.00%
Q2 2020$4,0000.0%88
+203.4%
0.00%
Q4 2019$4,000
+100.0%
290.0%0.00%
Q3 2019$2,0000.0%290.0%0.00%
Q2 2019$2,000
-33.3%
290.0%0.00%
Q1 2019$3,000
-97.5%
29
-97.6%
0.00%
Q4 2018$121,000
-17.1%
1,201
+3.9%
0.00%
Q3 2018$146,000
-2.0%
1,156
-34.9%
0.00%
Q2 2018$149,000
+38.0%
1,775
+1.4%
0.00%
Q1 2018$108,000
+881.8%
1,751
+821.6%
0.00%
Q4 2017$11,000
+175.0%
190
+156.8%
0.00%
Q3 2017$4,000
-66.7%
74
-26.0%
0.00%
Q2 2017$12,000
-90.8%
100
-91.3%
0.00%
Q1 2017$130,000
-62.0%
1,153
-44.4%
0.00%
-100.0%
Q3 2016$342,000
+245.5%
2,075
+198.1%
0.00%
Q2 2016$99,000
+1137.5%
696
+2075.0%
0.00%
Q2 2014$8,000
-98.3%
32
-97.8%
0.00%
-100.0%
Q1 2014$484,000
+1692.6%
1,469
+267.2%
0.00%
Q4 2013$27,000
-75.9%
400
-84.0%
0.00%
-100.0%
Q2 2013$112,0002,5000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders